⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 2026Transplantation and Cellular Therapy

Intratumoral Cellular Therapy with Autologous Activated M1 Sirpα-Low Macrophages In Non-Hodgkin Lymphoma: Clinical Results from a First-In-Human Phase 1 Study

Paolo Strati Tatyana Feldman Koby Kidder Devika Schirloff Steven Ruck Nathanael McCurley Jelle Kijlstra Christiane Querfeld

View at Publisher

Ask AI

Bookmark

Share

Key Points

Activated M1 macrophages may improve treatment outcomes in non-Hodgkin lymphoma, enhancing immune response.
Clinical results indicate a favorable safety profile and signaling pathways activation within tumor microenvironments.
Intratumoral cellular therapy was employed in a first-in-human phase 1 study, focusing on macrophage activation and interaction with cancer cells.
Future research may confirm the significance of combined therapies to increase efficacy; further studies are suggested.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase 1 study demonstrates potential of activated M1 macrophages in treating non-Hodgkin lymphoma, suggesting clinical viability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strati et al. (2026) studied this question.

synapsesocial.com/papers/69a76025c6e9836116a2c991 https://doi.org/10.1016/j.jtct.2025.12.099

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD StatusTransplantation and Cellular Therapy · 2026
2Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesTransplantation and Cellular Therapy · 2026
3Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017–2022)Transplantation and Cellular Therapy · 2026
4Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-adapted Prevention StrategyTransplantation and Cellular Therapy · 2026
5Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over timeTransplantation and Cellular Therapy · 2026

Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French ExperienceTransplantation and Cellular Therapy · 2026
Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective AnalysisTransplantation and Cellular Therapy · 2026
Lung Complications after Allogeneic Hematopoietic Cell Transplant and Outcomes: Implications Beyond Bronchiolitis Obliterans SyndromeTransplantation and Cellular Therapy · 2026
A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy · 2026
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regressionTransplantation and Cellular Therapy · 2026

TMore from Transplantation and Cellular Therapy

More from The University of Texas MD Anderson Cancer Center

More from City of Hope

More from Hackensack University Medical Center

More from University of Boyaca

More from C & L Instruments (United States)